Skip to content
mapperlab
← Dashboard
Stock

PCVX

VAXCYTE, INC.
Latest close $488 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
8
27 funds tracked
Ever held
10
Current + past
New this quarter
1
Exited this quarter
1

Marquee-fund ownership over time

May 15, 2024Feb 13, 2025Nov 14, 2025May 15, 2026
Now
8

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Maverick Capital$72$48-32%
D.E. Shaw$77$48-37%
AQR Capital Management re-entered$77$48-37%
Millennium Management$77$48-37%
Point72 Asset Management re-entered$93$48-48%
Renaissance Technologies$84$48-42%
Two Sigma Investments$31$48+54%
Bridgewater Associates re-entered$46$48+6%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Citadel Advisors→ $52-43%
Duquesne Family Office→ $31-67%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Vaxcyte, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
1
Filings · last 90d
10
Total on file
353
Recent SEC buffer
Most recent
Jun 3, 2026

30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 353 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · VAXCYTE, INC.

Annual figures sourced directly from VAXCYTE, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Net income
-$766.63M
FY2025-65% YoY
EPS (diluted)
$-5.63
FY2025-48% YoY
Free cash flow(?)
-$669.29M
FY2025-41% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Vaxcyte, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Bridgewater AssociatesQ2 2026open$52$47-10%
AQR Capital ManagementQ1 2026open$53$48-9%
Point72 Asset ManagementQ4 2025open$49$48-1%
Bridgewater AssociatesQ4 2025Q1 2026$46$54+19%
Two Sigma InvestmentsQ3 2025open$31$48+54%
Renaissance TechnologiesQ1 2025open$84$48-42%
Citadel AdvisorsQ4 2024Q2 2026$93$52-43%
Duquesne Family OfficeQ4 2024Q2 2025$93$31-67%
Point72 Asset ManagementQ4 2024Q3 2025$93$31-66%
D.E. ShawQ3 2024open$77$48-37%
AQR Capital ManagementQ3 2024Q4 2025$77$49-37%
Millennium ManagementQ3 2024open$77$48-37%
Maverick CapitalQ2 2024open$72$47-34%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.